Roy Morello
Concepts (207)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Osteogenesis Imperfecta | 13 | 2022 | 39 | 4.460 |
Why?
| Collagen Type I | 6 | 2022 | 97 | 2.340 |
Why?
| Extracellular Matrix Proteins | 9 | 2020 | 75 | 1.980 |
Why?
| Bone and Bones | 9 | 2021 | 516 | 1.840 |
Why?
| Molecular Chaperones | 9 | 2020 | 64 | 1.380 |
Why?
| Autoantigens | 3 | 2017 | 64 | 1.160 |
Why?
| Mutation | 12 | 2022 | 1501 | 1.080 |
Why?
| Collagen | 6 | 2022 | 223 | 1.040 |
Why?
| Endoplasmic Reticulum | 3 | 2017 | 123 | 1.010 |
Why?
| Procollagen-Proline Dioxygenase | 3 | 2017 | 9 | 1.010 |
Why?
| Ehlers-Danlos Syndrome | 2 | 2022 | 6 | 1.010 |
Why?
| Proteins | 7 | 2018 | 376 | 0.890 |
Why?
| Disease Models, Animal | 6 | 2022 | 1639 | 0.890 |
Why?
| Protein Processing, Post-Translational | 5 | 2020 | 183 | 0.840 |
Why?
| Cell Culture Techniques | 1 | 2021 | 112 | 0.790 |
Why?
| Endocrinology | 1 | 2020 | 13 | 0.770 |
Why?
| Mice | 21 | 2023 | 6413 | 0.760 |
Why?
| Gene Expression | 2 | 2021 | 664 | 0.740 |
Why?
| Osteocytes | 1 | 2021 | 220 | 0.670 |
Why?
| Gene Targeting | 1 | 2018 | 32 | 0.660 |
Why?
| Rare Diseases | 1 | 2018 | 46 | 0.650 |
Why?
| Animals | 22 | 2023 | 14385 | 0.610 |
Why?
| Mice, Knockout | 10 | 2023 | 926 | 0.600 |
Why?
| Bone Diseases | 1 | 2018 | 109 | 0.600 |
Why?
| Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase | 1 | 2016 | 7 | 0.570 |
Why?
| Homeostasis | 3 | 2023 | 223 | 0.510 |
Why?
| Gene Expression Regulation, Developmental | 3 | 2010 | 151 | 0.460 |
Why?
| Lung | 3 | 2022 | 507 | 0.400 |
Why?
| Mice, Inbred C57BL | 10 | 2020 | 1999 | 0.400 |
Why?
| Hydroxylation | 4 | 2017 | 61 | 0.390 |
Why?
| Connective Tissue Diseases | 1 | 2010 | 15 | 0.370 |
Why?
| Bone Development | 1 | 2010 | 69 | 0.360 |
Why?
| Cells, Cultured | 4 | 2020 | 1737 | 0.350 |
Why?
| Syndactyly | 1 | 2008 | 4 | 0.340 |
Why?
| Extremities | 1 | 2008 | 27 | 0.330 |
Why?
| Cartilage | 1 | 2008 | 47 | 0.330 |
Why?
| Osteogenesis | 3 | 2020 | 377 | 0.290 |
Why?
| Extracellular Matrix | 2 | 2018 | 111 | 0.290 |
Why?
| DNA | 1 | 2010 | 581 | 0.290 |
Why?
| Membrane Proteins | 2 | 2008 | 389 | 0.280 |
Why?
| Energy Metabolism | 2 | 2023 | 311 | 0.280 |
Why?
| X-Ray Microtomography | 2 | 2022 | 82 | 0.270 |
Why?
| Humans | 21 | 2023 | 54284 | 0.250 |
Why?
| NAD | 1 | 2023 | 46 | 0.230 |
Why?
| Relaxin | 1 | 2022 | 3 | 0.230 |
Why?
| Chondrocytes | 3 | 2008 | 37 | 0.220 |
Why?
| Collagen Type V | 1 | 2022 | 4 | 0.220 |
Why?
| Haploinsufficiency | 1 | 2022 | 13 | 0.220 |
Why?
| Proteoglycans | 2 | 2014 | 96 | 0.200 |
Why?
| Cyclophilins | 3 | 2016 | 13 | 0.190 |
Why?
| Calcification, Physiologic | 2 | 2020 | 42 | 0.190 |
Why?
| Membrane Glycoproteins | 2 | 2014 | 269 | 0.180 |
Why?
| Craniofacial Abnormalities | 1 | 2020 | 27 | 0.180 |
Why?
| Insulin | 3 | 2022 | 510 | 0.180 |
Why?
| Fractures, Bone | 1 | 2020 | 119 | 0.180 |
Why?
| Mice, Transgenic | 3 | 2018 | 656 | 0.170 |
Why?
| Transcriptome | 1 | 2021 | 346 | 0.170 |
Why?
| Male | 12 | 2022 | 27334 | 0.170 |
Why?
| Osteitis Deformans | 1 | 2018 | 3 | 0.170 |
Why?
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2018 | 7 | 0.170 |
Why?
| Calcium, Dietary | 1 | 2018 | 15 | 0.170 |
Why?
| Rabbits | 2 | 2018 | 425 | 0.160 |
Why?
| Chondrogenesis | 2 | 2008 | 13 | 0.160 |
Why?
| Gene-Environment Interaction | 1 | 2018 | 44 | 0.160 |
Why?
| DNA Breaks, Double-Stranded | 1 | 2018 | 78 | 0.160 |
Why?
| Fibroblasts | 3 | 2010 | 386 | 0.160 |
Why?
| Osteochondrodysplasias | 2 | 2008 | 14 | 0.150 |
Why?
| Metabolic Networks and Pathways | 1 | 2018 | 104 | 0.150 |
Why?
| Molecular Targeted Therapy | 1 | 2018 | 128 | 0.150 |
Why?
| Testis | 2 | 2022 | 65 | 0.150 |
Why?
| Pelvis | 1 | 2017 | 76 | 0.150 |
Why?
| Mice, Mutant Strains | 2 | 2014 | 84 | 0.140 |
Why?
| Lysine | 1 | 2017 | 102 | 0.140 |
Why?
| Cell Line | 3 | 2016 | 1153 | 0.140 |
Why?
| Calcium | 1 | 2018 | 432 | 0.140 |
Why?
| Virulence | 1 | 2016 | 194 | 0.130 |
Why?
| Virulence Factors | 1 | 2016 | 92 | 0.130 |
Why?
| DNA Mutational Analysis | 4 | 2011 | 217 | 0.130 |
Why?
| Female | 7 | 2022 | 28441 | 0.130 |
Why?
| Cell Differentiation | 2 | 2008 | 720 | 0.130 |
Why?
| Osteomyelitis | 1 | 2016 | 122 | 0.130 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 570 | 0.120 |
Why?
| Molecular Sequence Data | 4 | 2011 | 980 | 0.120 |
Why?
| Organ Size | 1 | 2014 | 237 | 0.120 |
Why?
| Polymerase Chain Reaction | 3 | 2010 | 531 | 0.110 |
Why?
| Staphylococcus aureus | 1 | 2016 | 361 | 0.110 |
Why?
| In Situ Hybridization | 2 | 2010 | 82 | 0.110 |
Why?
| Bacterial Proteins | 1 | 2016 | 454 | 0.110 |
Why?
| Serpins | 1 | 2011 | 7 | 0.110 |
Why?
| Nerve Growth Factors | 1 | 2011 | 32 | 0.100 |
Why?
| Eye Proteins | 1 | 2011 | 19 | 0.100 |
Why?
| Rats | 1 | 2018 | 3415 | 0.100 |
Why?
| Cell Proliferation | 3 | 2010 | 1096 | 0.100 |
Why?
| Skin | 2 | 2017 | 469 | 0.100 |
Why?
| Amino Acid Sequence | 3 | 2010 | 767 | 0.100 |
Why?
| Cell Respiration | 1 | 2010 | 51 | 0.100 |
Why?
| Proline | 1 | 2010 | 31 | 0.090 |
Why?
| Connective Tissue | 1 | 2010 | 23 | 0.090 |
Why?
| Ascorbic Acid | 1 | 2010 | 33 | 0.090 |
Why?
| Fluorescent Antibody Technique | 1 | 2010 | 141 | 0.090 |
Why?
| Osteoporosis | 2 | 2010 | 164 | 0.090 |
Why?
| Mitochondrial Proteins | 1 | 2010 | 121 | 0.090 |
Why?
| Tandem Mass Spectrometry | 1 | 2010 | 248 | 0.080 |
Why?
| Blotting, Northern | 1 | 2008 | 108 | 0.080 |
Why?
| In Situ Nick-End Labeling | 1 | 2008 | 64 | 0.080 |
Why?
| GATA Transcription Factors | 1 | 2008 | 4 | 0.080 |
Why?
| Receptors, G-Protein-Coupled | 2 | 2022 | 55 | 0.080 |
Why?
| Fibrillar Collagens | 1 | 2006 | 3 | 0.070 |
Why?
| RNA, Messenger | 2 | 2010 | 1202 | 0.070 |
Why?
| Mitochondria | 1 | 2010 | 489 | 0.070 |
Why?
| Immunohistochemistry | 3 | 2020 | 1089 | 0.070 |
Why?
| Bone Diseases, Metabolic | 1 | 2006 | 82 | 0.070 |
Why?
| Osteoclasts | 2 | 2020 | 469 | 0.060 |
Why?
| Kidney | 1 | 2010 | 820 | 0.060 |
Why?
| Collagen Type X | 1 | 2003 | 3 | 0.060 |
Why?
| Receptors, Peptide | 1 | 2022 | 10 | 0.060 |
Why?
| Gonadal Steroid Hormones | 1 | 2022 | 42 | 0.050 |
Why?
| Transcription Factors | 2 | 2003 | 622 | 0.050 |
Why?
| Capillary Permeability | 1 | 2002 | 40 | 0.050 |
Why?
| Apoptosis | 1 | 2008 | 1300 | 0.050 |
Why?
| Kidney Glomerulus | 1 | 2002 | 61 | 0.050 |
Why?
| Multiple Myeloma | 1 | 2017 | 3035 | 0.050 |
Why?
| Oxidation-Reduction | 1 | 2023 | 382 | 0.050 |
Why?
| Adult | 5 | 2022 | 14207 | 0.050 |
Why?
| Neoplasm Proteins | 1 | 2003 | 359 | 0.050 |
Why?
| Periodontal Ligament | 1 | 2020 | 2 | 0.050 |
Why?
| Osteoblasts | 2 | 2016 | 514 | 0.050 |
Why?
| Skull | 1 | 2020 | 79 | 0.050 |
Why?
| Cytokines | 1 | 2023 | 676 | 0.040 |
Why?
| Time Factors | 1 | 2006 | 3213 | 0.040 |
Why?
| Gene Expression Regulation | 1 | 2003 | 1062 | 0.040 |
Why?
| Dentin | 1 | 2017 | 6 | 0.040 |
Why?
| Infant, Newborn | 3 | 2011 | 2907 | 0.040 |
Why?
| Cross-Linking Reagents | 1 | 2017 | 42 | 0.040 |
Why?
| Phenotype | 1 | 2020 | 820 | 0.040 |
Why?
| Alkaline Phosphatase | 1 | 2017 | 99 | 0.040 |
Why?
| Cornea | 1 | 2017 | 62 | 0.040 |
Why?
| Operon | 1 | 2016 | 38 | 0.040 |
Why?
| Core Binding Factor Alpha 1 Subunit | 2 | 2008 | 48 | 0.040 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 171 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 243 | 0.030 |
Why?
| Aorta | 1 | 2017 | 177 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2017 | 313 | 0.030 |
Why?
| Skeleton | 1 | 2014 | 1 | 0.030 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2016 | 244 | 0.030 |
Why?
| Gene Knock-In Techniques | 1 | 2014 | 30 | 0.030 |
Why?
| Protein Interaction Maps | 1 | 2014 | 24 | 0.030 |
Why?
| Protein Folding | 1 | 2014 | 52 | 0.030 |
Why?
| Proteomics | 1 | 2016 | 343 | 0.030 |
Why?
| Staphylococcal Infections | 1 | 2016 | 300 | 0.030 |
Why?
| Pedigree | 1 | 2011 | 146 | 0.030 |
Why?
| Tomography, X-Ray Computed | 1 | 2017 | 1213 | 0.020 |
Why?
| Spermatocytes | 1 | 2010 | 3 | 0.020 |
Why?
| Spermatids | 1 | 2010 | 3 | 0.020 |
Why?
| Leydig Cells | 1 | 2010 | 3 | 0.020 |
Why?
| Sertoli Cells | 1 | 2010 | 3 | 0.020 |
Why?
| Base Sequence | 1 | 2011 | 719 | 0.020 |
Why?
| RNA Interference | 1 | 2010 | 195 | 0.020 |
Why?
| Flavonoids | 1 | 2010 | 62 | 0.020 |
Why?
| HeLa Cells | 1 | 2010 | 291 | 0.020 |
Why?
| Transfection | 1 | 2010 | 399 | 0.020 |
Why?
| Phylogeny | 1 | 2010 | 269 | 0.020 |
Why?
| Stilbenes | 1 | 2010 | 65 | 0.020 |
Why?
| Oxygen Consumption | 1 | 2010 | 223 | 0.020 |
Why?
| Adenosine Triphosphate | 1 | 2010 | 242 | 0.020 |
Why?
| Consanguinity | 1 | 2008 | 15 | 0.020 |
Why?
| Cyclic AMP | 1 | 2009 | 106 | 0.020 |
Why?
| Growth Plate | 1 | 2008 | 11 | 0.020 |
Why?
| Loss of Heterozygosity | 1 | 2008 | 97 | 0.020 |
Why?
| Prenatal Diagnosis | 1 | 2008 | 108 | 0.020 |
Why?
| Transcriptional Activation | 1 | 2008 | 134 | 0.020 |
Why?
| Antioxidants | 1 | 2010 | 297 | 0.020 |
Why?
| Plant Extracts | 1 | 2010 | 193 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2011 | 1304 | 0.020 |
Why?
| Absorptiometry, Photon | 1 | 2008 | 174 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 673 | 0.020 |
Why?
| Genes, Recessive | 1 | 2006 | 18 | 0.020 |
Why?
| Repressor Proteins | 1 | 2008 | 165 | 0.020 |
Why?
| Bone Density | 1 | 2009 | 416 | 0.020 |
Why?
| Models, Biological | 1 | 2010 | 823 | 0.020 |
Why?
| Radiography | 1 | 2006 | 524 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2009 | 1476 | 0.020 |
Why?
| Ultrasonography, Prenatal | 1 | 2006 | 177 | 0.020 |
Why?
| Cell Line, Tumor | 1 | 2009 | 1550 | 0.020 |
Why?
| Humerus | 1 | 2003 | 21 | 0.010 |
Why?
| Embryo, Mammalian | 1 | 2003 | 68 | 0.010 |
Why?
| Hypertrophy | 1 | 2003 | 52 | 0.010 |
Why?
| Aged | 1 | 2017 | 10054 | 0.010 |
Why?
| Infant | 1 | 2011 | 3817 | 0.010 |
Why?
| Femur | 1 | 2003 | 144 | 0.010 |
Why?
| Child, Preschool | 1 | 2011 | 4147 | 0.010 |
Why?
| LIM-Homeodomain Proteins | 1 | 2002 | 2 | 0.010 |
Why?
| Collagen Type IV | 1 | 2002 | 14 | 0.010 |
Why?
| Basement Membrane | 1 | 2002 | 22 | 0.010 |
Why?
| Laminin | 1 | 2002 | 29 | 0.010 |
Why?
| Binding Sites | 1 | 2003 | 440 | 0.010 |
Why?
| Cytoskeletal Proteins | 1 | 2002 | 58 | 0.010 |
Why?
| Glomerular Filtration Rate | 1 | 2002 | 138 | 0.010 |
Why?
| Blood Proteins | 1 | 2002 | 100 | 0.010 |
Why?
| Homeodomain Proteins | 1 | 2002 | 82 | 0.010 |
Why?
| Transcription, Genetic | 1 | 2003 | 418 | 0.010 |
Why?
| Middle Aged | 1 | 2017 | 13088 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 2002 | 368 | 0.010 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 208 | 0.010 |
Why?
| Promoter Regions, Genetic | 1 | 2003 | 520 | 0.010 |
Why?
| Adolescent | 1 | 2011 | 6897 | 0.010 |
Why?
| Child | 1 | 2011 | 7341 | 0.010 |
Why?
|
|
Morello's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|